ThromboGenics reveals additional Phase III ocriplasmin data
This article was originally published in Scrip
Executive Summary
As ThromboGenics revealed additional results from its pivotal Phase III program for its retinal disease product, ocriplasmin, the company once again reaffirmed that it is on track for European and US regulatory filings by year-end.